Legal Representation
Attorney
Eva Gullick Frongello
USPTO Deadlines
Application History
21 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Aug 28, 2023 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Aug 28, 2023 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| May 8, 2023 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| May 8, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| May 8, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| May 8, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| May 8, 2023 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Jan 24, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Nov 29, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Nov 29, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Nov 9, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Oct 24, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Oct 12, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Oct 12, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 12, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 11, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 11, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| May 11, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 10, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 4, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Aug 13, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
pharmaceutical preparations, namely, cell therapy products utilizing t-cell therapy for use in treating disease; cell-based immunotherapeutic treatment by way of genetically modified cells for use in human therapeutics and the treatment of cancer; pharmaceuticals for the treatment of cancer; pharmaceutical preparations in the nature of genetically modified cells, namely, genetically modified immune cells for use in human therapeutics and in the treatment of cancer
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
pharmaceutical research and development services; scientific research in the field of cellular immunotherapy utilizing chimeric antigen receptor t cells for use in treating cancer
First Use Anywhere:
0
First Use in Commerce:
0
Class 044
Medical services, namely, cellular immunotherapy treatments utilizing chimeric antigen receptor t cells for use in treating disease, namely, the treatment of cancer
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Pseudo Mark
PRECISION BIOSCIENCES STEALTH
Classification
International Classes
005
042
044